DK2658872T3 - Polypeptid, der binder aberrerende celler og inducerer apoptose - Google Patents
Polypeptid, der binder aberrerende celler og inducerer apoptose Download PDFInfo
- Publication number
- DK2658872T3 DK2658872T3 DK11820898.2T DK11820898T DK2658872T3 DK 2658872 T3 DK2658872 T3 DK 2658872T3 DK 11820898 T DK11820898 T DK 11820898T DK 2658872 T3 DK2658872 T3 DK 2658872T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- binds
- induces apoptosis
- aberrant cells
- aberrant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061460212P | 2010-12-27 | 2010-12-27 | |
PCT/NL2011/050891 WO2012091563A1 (en) | 2010-12-27 | 2011-12-22 | A polypeptide that binds aberrant cells and induces apoptosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2658872T3 true DK2658872T3 (da) | 2020-10-12 |
Family
ID=45771866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11820898.2T DK2658872T3 (da) | 2010-12-27 | 2011-12-22 | Polypeptid, der binder aberrerende celler og inducerer apoptose |
Country Status (5)
Country | Link |
---|---|
US (2) | US9821073B2 (da) |
EP (2) | EP3778642A1 (da) |
CA (1) | CA2822938A1 (da) |
DK (1) | DK2658872T3 (da) |
WO (1) | WO2012091563A1 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012091564A2 (en) | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
EP3778642A1 (en) | 2010-12-27 | 2021-02-17 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
WO2013048243A1 (en) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
JP2015504895A (ja) * | 2012-01-13 | 2015-02-16 | エーピーオー‐ティー ビー.ヴイ. | 毒性部分を備える異常細胞拘束性免疫グロブリン |
WO2015197639A1 (en) * | 2014-06-23 | 2015-12-30 | Vib Vzw | Tissue-specific cell depletion with two chimeric proteins |
EP3200830B1 (en) | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
GB201417803D0 (en) | 2014-10-08 | 2014-11-19 | Adaptimmune Ltd | T cell receptors |
WO2016077720A1 (en) * | 2014-11-14 | 2016-05-19 | Protein One, Llc | Binding agents and uses thereof |
US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
KR20200021074A (ko) | 2017-06-14 | 2020-02-27 | 아디셋 바이오, 인크. | Hla 제한된 방식으로 hla-a2/tyrd를 결합할 수 있는 항체 및 이의 용도 |
WO2019233605A1 (en) * | 2018-06-08 | 2019-12-12 | BioNTech SE | Compositions and methods for diagnosis and treatment of cancer |
EP4110823A1 (en) * | 2020-02-26 | 2023-01-04 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
CN114181322A (zh) * | 2021-12-13 | 2022-03-15 | 厦门医学院 | 一种抑制肺癌细胞增殖的多肽 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK286235B6 (sk) | 1997-08-12 | 2008-06-06 | Leadd B. V. | Spôsob zisťovania transformačnej schopnosti látky, spôsob zisťovania predispozície buniek stať sa nádorovými bunkami, použitie nukleovej kyseliny a diagnostická súprava |
ES2321485T3 (es) | 2001-03-30 | 2009-06-08 | Leadd B.V. | Proteinas de fusion para tratamiento especifico de cancer y de enfermedades autoinmunes. |
JP4049297B2 (ja) | 2001-06-11 | 2008-02-20 | 株式会社ルネサステクノロジ | 半導体記憶装置 |
AU2003214721A1 (en) | 2002-04-19 | 2003-11-03 | Leadd B.V. | Fragments of apoptin |
JP2006523437A (ja) | 2002-12-03 | 2006-10-19 | アヴィデックス リミテッド | レセプター複合体 |
CA2570458C (en) | 2004-06-09 | 2014-05-20 | Technion Research & Development Foundation Ltd. | Antibodies for selective apoptosis of cells |
US20090208502A1 (en) | 2005-12-20 | 2009-08-20 | Ralph Alexander Willemsen | Apoptosis-inducing protein complexes and therapeutic use thereof |
AU2008234530B2 (en) * | 2007-03-29 | 2013-03-28 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
WO2009131435A1 (en) * | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
BRPI0921586A2 (pt) * | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
US20130131088A1 (en) * | 2010-01-13 | 2013-05-23 | University Health Network | Treating cancer with statins and compounds having dipyridamole activity |
EP3778642A1 (en) | 2010-12-27 | 2021-02-17 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
WO2012091564A2 (en) | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
-
2011
- 2011-12-22 EP EP20195939.2A patent/EP3778642A1/en not_active Withdrawn
- 2011-12-22 DK DK11820898.2T patent/DK2658872T3/da active
- 2011-12-22 EP EP11820898.2A patent/EP2658872B1/en active Active
- 2011-12-22 CA CA2822938A patent/CA2822938A1/en not_active Abandoned
- 2011-12-22 US US13/976,974 patent/US9821073B2/en active Active
- 2011-12-22 WO PCT/NL2011/050891 patent/WO2012091563A1/en active Application Filing
-
2017
- 2017-11-20 US US15/818,225 patent/US20180071398A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2658872A1 (en) | 2013-11-06 |
US20140205599A1 (en) | 2014-07-24 |
EP2658872B1 (en) | 2020-09-30 |
CA2822938A1 (en) | 2012-07-05 |
WO2012091563A1 (en) | 2012-07-05 |
EP3778642A1 (en) | 2021-02-17 |
US20180071398A1 (en) | 2018-03-15 |
US9821073B2 (en) | 2017-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2658872T3 (da) | Polypeptid, der binder aberrerende celler og inducerer apoptose | |
DK2994528T3 (da) | Organoider, der omfatter isolerede renale celler og anvendelser deraf | |
IL258409A (en) | Marking and scoring in daylight using a laser | |
DK2536830T3 (da) | Polypeptider | |
IL225897A0 (en) | 2cxcr-binding polypeptides | |
BRPI1014776A2 (pt) | autenticação multicamada baseada em modelo | |
DK2563400T3 (da) | Modificerede bindeproteiner, der hæmmer VEGF-A-receptorinteraktion | |
EP2430563A4 (en) | SYSTEMS AND METHODS FOR FRACTIONAL ROUTING REDUNDANCY | |
DK3663399T3 (da) | Modificerede factor IX-polypeptider og anvendelser deraf | |
BRPI1013029A2 (pt) | polipeptídeos bifuncionais | |
DK2635178T3 (da) | Elektromagnetiske sonder, fremgangsmåder til fremstilling deraf og fremgangsmåder, der anvender sådanne elektromagnetiske sonder | |
DK3620518T3 (da) | Amylasepolypeptid | |
BR112013011465A2 (pt) | impermeabilização soldada por indução | |
BR112012031000A2 (pt) | estrutura multicamadas, dispositivos e transformador | |
TWM388724U (en) | Chip type multilayer inductor | |
DK2658873T3 (da) | Tværbindende polypeptid omfattende et tetramerisk enkeltkæde-antistof, der binder et MHC-MAGE-kompleks, der inducerer apoptose | |
DK3085777T3 (da) | Polypeptid | |
DK2566689T3 (da) | Flerlagsrør | |
IL223721A0 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
GB201016494D0 (en) | Polypeptide | |
BRPI1013716A2 (pt) | 5-alquinil-piridinas. | |
FR2944149B1 (fr) | Electrode composite. | |
DE102008014880A8 (de) | Antientzündliches Polypeptid | |
IT1400884B1 (it) | Procedimento per realizzare materiale isolante. | |
IT1403037B1 (it) | Struttura multistrato e procedimento per la sua realizzazione |